LOGIN  |  REGISTER
Recursion
Terns Pharmaceuticals

Phreesia Awards Inducement Grants as Part of its Acquisition of Access eForms

August 15, 2023 | Last Trade: US$23.97 0.08 0.33

WILMINGTON, Del. / Aug 15, 2023 / Business Wire / On July 13, 2023, Phreesia, Inc.’s (“Phreesia”) Board of Directors approved the grant of restricted stock unit awards pursuant to Phreesia’s 2023 Inducement Award Plan (the “Plan”). On August 15, 2023, Phreesia made grants pursuant to the Plan in an aggregate amount of 12,285 shares of its common stock to 24 new non-executive employees to induce them to join Phreesia. The awards vest annually in equal installments over a four-year period following their grant, subject to continued employment. Each award was granted as a material inducement to employment in accordance with the NYSE Listed Company Manual Rule 303A.08.

About Phreesia

Phreesia is the trusted leader in patient activation, giving providers, health plans, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled more than 120 million patient visits in 2022–more than 1 in 10 visits across the U.S.–scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit www.phreesia.com.

Recursion

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page